Live webcast on Wednesday, August 28th at 3:20 PM ET
HOUSTON, TX / ACCESSWIRE / August 27, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:) (“CNS” or the “Company”), a biopharmaceutical company focused on the development of therapies for primary and metastatic cancers of the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, will present. and discuss the latest business events on LIVE! via Webull Corporate Connect: Virtual Biotech Investment Webinar on Wednesday, August 28, 2024 at 3:20 PM ET.
Conference Details:
Conference: LIVE! via Webull Corporate Connect: Virtual Biotech Investment Webinar
Date/Time: Wednesday, August 28, 2024 at 3:20 PM ET
Presenter: John Climaco, Chief Executive Officer
Registration Link: HERE
About Webbull Financial
Webull Financial is a leading online trading platform dedicated to empowering self-directed investors with innovative tools and advanced technology. With low-cost trading on a wide range of assets, advanced charting tools and real-time market data, Webull is changing the way people approach investing. A user-centric approach and commitment to staying ahead of industry trends underscores the goal of providing a seamless and beneficial experience to traders of all levels. Through the Webull Group, Webull Financial and its subsidiaries, come together to serve tens of millions of users from more than 180 countries around the world. Securities and futures trading is offered to clients by Webull Financial LLC (“Webull Financial”), a broker-dealer registered with the Securities and Exchange Commission (SEC) and a futures commission broker registered with the Commodity Futures Trading Commission (CFTC). Webull Financial is a member of the Financial Industry Authority (FINRA), the National Futures Association (NFA), and the Securities Investor Protection Corporation (SIPC). All investments are subject to risk, including potential loss of principal. For more information about Webull, visit www.webull.com.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anticancer drug candidates to treat primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline that appears to cross the blood brain barrier. Berubicin is currently being developed for the treatment of several indications of serious brain and CNS oncology including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook (NASDAQ:), and LinkedIn.
CONTACT:
Investor Contacts
The JTC Team, LLC
General Thomas
833-475-8247
CNSP@jtcir.com
SOURCE: CNS Pharmaceuticals, Inc.
View the original press release at accesswire.com
